These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17899074)

  • 1. Could choline PET play a role in malignancies other than prostate cancer?
    Nanni C; Rubello D; Fanti S
    Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):216-8. PubMed ID: 17899074
    [No Abstract]   [Full Text] [Related]  

  • 2. Imaging of a paraganglioma on C-11 choline PET/CT.
    Rahbar K; Fuchs M; Kemper S; Juergens KU; Weckesser M; Stegger L
    Clin Nucl Med; 2009 Feb; 34(2):119-21. PubMed ID: 19352271
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of trigger PSA and PSA kinetics on (11)C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Jadvar H
    J Nucl Med; 2010 Mar; 51(3):498-9; author reply 499-500. PubMed ID: 20150273
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate-specific antigen and radiolabelled choline PET/CT for the assessment of response to therapy: synergy or conflicting?
    Evangelista L; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):200-201. PubMed ID: 26493310
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis.
    Treglia G; Ceriani L; Sadeghi R; Giovacchini G; Giovanella L
    Clin Chem Lab Med; 2014 May; 52(5):725-33. PubMed ID: 24310773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of 11C-choline PET/CT for imaging prostate cancer: a pictorial guide.
    Murphy RC; Kawashima A; Peller PJ
    AJR Am J Roentgenol; 2011 Jun; 196(6):1390-8. PubMed ID: 21606304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11C-Choline PET/CT in the primary diagnosis of prostate cancer: impact on treatment planning.
    Garcia JR; Jorcano S; Soler M; Linero D; Moragas M; Riera E; Miralbell R; Lomeña F
    Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):342-50. PubMed ID: 24844254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [First experience of using positron emission tomography with 11C-choline in prostate cancer (PC)].
    Granov AM; Tiutin LA; Ryzhkova DV; Shkol'nik MI; Andabekov TT; Mostova MI; Shatik SV; Kostenikov NA; Zaĭtsev VV; Tlostanova MS; Stanzhevskiĭ AA; Panfilenko AA; Arzumanov AA; Metelëv VV; Iliushchenko IuR
    Vopr Onkol; 2013; 59(4):460-4. PubMed ID: 24032219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of PET/CT and current challenges in prostate cancer management.
    Lindholm P; Seppänen M; Minn H
    Nucl Med Commun; 2009 May; 30(5):325. PubMed ID: 19421025
    [No Abstract]   [Full Text] [Related]  

  • 10. The rising PET: the increasing use of choline PET/CT in prostate cancer.
    Chiti A; Picchio M
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):53-4. PubMed ID: 21103870
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pro and contra: 11C choline PET in diagnosis of prostate cancer].
    Kotzerke J; Zöphel K; Salomon G; Graefen M; Heidenreich A
    Aktuelle Urol; 2007 May; 38(3):189-94. PubMed ID: 17566231
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate cancer: Identifying sites of recurrence with choline-PET-CT imaging.
    Castellucci P; Fanti S
    Nat Rev Urol; 2015 Mar; 12(3):134-5. PubMed ID: 25447835
    [No Abstract]   [Full Text] [Related]  

  • 13. [11C-choline PET/CT in the diagnosis of prostate cancer -- Hungarian experience].
    Garai I; Farkas B; Oszlánszki A; Berczi C; Flaskó T; Galuska L
    Magy Onkol; 2015 Mar; 59(1):25-9. PubMed ID: 25763910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response assessment of hormonal therapy in prostate cancer by [11C] choline PET/CT.
    De Waele A; Van Binnebeek S; Mottaghy FM
    Clin Nucl Med; 2010 Sep; 35(9):701-3. PubMed ID: 20706046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer.
    Rinnab L; Blumstein NM; Mottaghy FM; Hautmann RE; Küfer R; Hohl K; Reske SN
    BJU Int; 2007 Jun; 99(6):1421-6. PubMed ID: 17355373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do we have to withdraw antiandrogenic therapy in prostate cancer patients before PET/CT with [11C]choline?
    Giovacchini G
    Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1964-6. PubMed ID: 21901380
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial comment on: 11C-choline-positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms.
    Chun FK
    Eur Urol; 2008 Aug; 54(2):400-1. PubMed ID: 18456392
    [No Abstract]   [Full Text] [Related]  

  • 19. [Diagnostic relevance of choline-PET / CT in patients with prostate cancer].
    Zengerling F; Schrader AJ; Schrader M; Jentzmik F
    Aktuelle Urol; 2012 Jan; 43(1):49-54. PubMed ID: 21769763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen.
    Giovacchini G; Picchio M; Garcia-Parra R; Mapelli P; Briganti A; Montorsi F; Gianolli L; Messa C
    J Urol; 2013 Jan; 189(1):105-10. PubMed ID: 23164385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.